Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016 - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016" report to their offering.

Huntingtin (Huntington Disease Protein or HTT) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 7 and 5 respectively.

Huntingtin (Huntington Disease Protein or HTT) Huntingtin protein is an encoded by the huntingtin gene, also called the HTT or HD (Huntington disease) gene. Huntingtin up regulates the expression of brain derived neurotrophic factor (BDNF) at the transcription level. Huntingtin is primarily associated with vesicles and microtubules. These indicate an important role in cytoskeletal anchoring or transport of mitochondria. The Htt protein is involved in vesicle trafficking as it interacts with HIP1 to mediate endocytosis. Huntingtin also plays an important role in the establishment in epithelial polarity through its interaction with RAB11A.

Huntingtin - Pipeline Review, H2 2016, outlays comprehensive information on the Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

1. Introduction
2. Huntingtin (Huntington Disease Protein or HTT) Overview
3. Therapeutics Development
4. Pipeline Products for Huntingtin (Huntington Disease Protein or HTT) - Overview
5. Pipeline Products for Huntingtin (Huntington Disease Protein or HTT) - Comparative Analysis
6. Huntingtin (Huntington Disease Protein or HTT) - Therapeutics under Development by Companies
7. Huntingtin (Huntington Disease Protein or HTT) - Therapeutics under Investigation by Universities/Institutes
8. Huntingtin (Huntington Disease Protein or HTT) Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Huntingtin (Huntington Disease Protein or HTT) - Products under Development by Companies
13. Huntingtin (Huntington Disease Protein or HTT) - Products under Investigation by Universities/Institutes
14. Huntingtin (Huntington Disease Protein or HTT) - Companies Involved in Therapeutics Development

• AFFiRiS AG
• Ionis Pharmaceuticals, Inc.
• Neurimmune Holding AG
• nLife Therapeutics, S.L.
• reMYND NV
• Shire Plc
• UniQure N.V.
• Voyager Therapeutics, Inc.
• Vybion, Inc.
• WAVE Life Sciences Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/2gh5lh/huntingtin